Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review

World Journal of Surgical Oncology

Zhixian Gao¹  Lanbing Yu¹  Shuyu Hao¹  Yunpeng Liu¹ 

[1] China National Clinical Research Center for Neurological Diseases, No. 6 Tiantan Xili, Dongcheng District, Beijing, China

关键词: Long-term chemotherapy;    Temozolomide;    Thalamus;    Deep-seated;    Multifocal glioblastoma;   

Others  :  1175222
DOI  :  10.1186/s12957-015-0558-x

 received in 2014-10-16, accepted in 2015-03-23,  发布年份 2015

【 摘 要 】

Background

Multifocal glioblastoma is an uncommon and refractory subtype of high-grade glioma since the burden of masses could not be eliminated simply by operation, and it is getting even harder to control if some deep structures, like thalamus and pineal region, are involved.

Case presentation

Here we report a case of a 30-year-old male with multifocal glioblastoma affected his right thalamus, left lateral ventricle, and pineal region. Clinical manifestations include operation, concurrent radiochemotherapy, and a 12-cycle adjuvant temozolomide administration. The masses of this patient nearly disappeared after 15 months from the primary diagnosis, and no severe adverse event or neurological sequel occurred.

Conclusions

Long-term temozolomide might be an optimal choice for patients with multifocal glioblastoma, especially with deep-seated structure involvement.

【 授权许可】

   
2015 Liu et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al.. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987-96.
• [2]Batzdorf U, Malamud N. The problem of multicentric gliomas. J Neurosurg. 1963; 20:122-36.
• [3]Hassaneen W, Levine NB, Suki D, Salaskar AL, de Moura LA, McCutcheon IE et al.. Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. J Neurosurg. 2011; 114:576-84.
• [4]Salvati M, Caroli E, Orlando ER, Frati A, Artizzu S, Ferrante L. Multicentric glioma: our experience in 25 patients and critical review of the literature. Neurosurg Rev. 2003; 26:275-9.
• [5]Showalter TN, Andrel J, Andrews DW, Curran WJ, Daskalakis C, Werner-Wasik M. Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys. 2007; 69:820-4.
• [6]Darlix A, Baumann C, Lorgis V, Ghiringhelli F, Blonski M, Chauffert B et al.. Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. Anticancer Res. 2013; 33:3467-74.
• [7]Galldiks N, Berhorn T, Blau T, Dunkl V, Fink GR, Schroeter M. “One week on-one week off”: efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center. J Neurooncol. 2013; 112:209-15.
• [8]Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. J Neurooncol. 2012; 108:173-7.
• [9]Seiz M, Krafft U, Freyschlag CF, Weiss C, Schmieder K, Lohr F et al.. Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. J Cancer Res Clin Oncol. 2010; 136:1691-5.
• [10]Barnard RO, Geddes JF. The incidence of multifocal cerebral gliomas. A histologic study of large hemisphere sections. Cancer. 1987; 60:1519-31.
• [11]Djalilian HR, Shah MV, Hall WA. Radiographic incidence of multicentric malignant gliomas. Surg Neurol. 1999; 51:554-7. discussion 557–558
• [12]Thomas RP, Xu LW, Lober RM, Li G, Nagpal S. The incidence and significance of multiple lesions in glioblastoma. J Neurooncol. 2013; 112:91-7.
• [13]Bailey S, Skinner R, Lucraft HH, Perry RH, Todd N, Pearson AD. Pineal tumours in the north of England 1968–93. Arch Dis Child. 1996; 75:181-5.
• [14]Bradfield JS, Perez CA. Pineal tumors and ectopic pinealomas. Analysis of treatment and failures. Radiology. 1972; 103:399-406.
• [15]Lou E, Peters KB, Sumrall AL, Desjardins A, Reardon DA, Lipp ES et al.. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med. 2013; 2:185-95.
• [16]Kyritsis AP, Levin VA, Yung WK, Leeds NE. Imaging patterns of multifocal gliomas. Eur J Radiol. 1993; 16:163-70.
• [17]Quinones-Hinojosa A, Sanai N, Soriano-Navarro M, Gonzalez-Perez O, Mirzadeh Z, Gil-Perotin S et al.. Cellular composition and cytoarchitecture of the adult human subventricular zone: a niche of neural stem cells. J Comp Neurol. 2006; 494:415-34.
• [18]Sanai N, Tramontin AD, Quinones-Hinojosa A, Barbaro NM, Gupta N, Kunwar S et al.. Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature. 2004; 427:740-4.
• [19]Lim DA, Cha S, Mayo MC, Chen MH, Keles E, VandenBerg S et al.. Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol. 2007; 9:424-9.
• [20]Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al.. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275:1943-7.
• [21]Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012; 13:283-96.
• [22]Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al.. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997; 15:356-62.
• [23]Krex D, Mohr B, Appelt H, Schackert HK, Schackert G. Genetic analysis of a multifocal glioblastoma multiforme: a suitable tool to gain new aspects in glioma development. Neurosurgery. 2003; 53:1377-84. discussion 1384
• [24]Xu J, Li Z, Wang J, Chen H, Fang JY. Combined PTEN mutation and protein expression associate with overall and disease-free survival of glioblastoma patients. Transl Oncol. 2014;7:196–205.e191.
• [25]Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B et al.. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007; 11:69-82.
• [26]Wu L, Yang T, Deng X, Yang C, Zhao L, Fang J et al.. Surgical outcomes in spinal cord subependymomas: an institutional experience. J Neurooncol. 2014; 116:99-106.
• [27]Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB et al.. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006; 66:7843-8.
• [28]Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H et al.. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World J Surg Oncol. 2013; 11:284. BioMed Central Full Text
• [29]Balana C, Vaz MA, Lopez D, de la Penas R, Garcia-Bueno JM, Molina-Garrido MJ et al.. Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain. Clin Transl Oncol. 2014; 16:273-9.
• [30]Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA et al.. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013; 31:4085-91.
• [31]Eoli M, Menghi F, Bruzzone MG, De Simone T, Valletta L, Pollo B et al.. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res. 2007; 13:2606-13.
• [32]Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M et al.. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008; 26:4189-99.
• [33]Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R et al.. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer. 2009; 101:124-31.
• [34]Restrepo DZO, Yaguna CE. Models with radiative neutrino masses and viable dark matter candidates. J High Energy Phys. 2013; 2013:1-37.
• [35]Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG et al.. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008; 9:29-38.
• [36]Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol. 2012;14 Suppl 4:iv100–108.
• [37]Hau P, Koch D, Hundsberger T, Marg E, Bauer B, Rudolph R et al.. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology. 2007; 68:688-90.